Form 4: Bio-Techne Director Roeland Nusse Reports Acquisition of Common Stock and Stock Options
SEC Form 4 Filing
Director Roeland Nusse reports acquiring common stock and stock options in Bio-Techne Corp on October 24, 2024.
Summary
- Roeland Nusse, a director of Bio-Techne Corp, filed a Form 4 on October 28, 2024, reporting changes in beneficial ownership.
- On October 24, 2024, Nusse acquired 1,462 shares of common stock at $0 and disposed of 44,559 shares.
- Nusse also acquired 3,511 stock options with an exercise price of $68.37, exercisable starting October 24, 2024, and expiring on October 24, 2034.
- Following these transactions, Nusse directly owns various stock options with exercise prices ranging from $21.84 to $128.81 and expiration dates between 2025 and 2033.
- The newly acquired options vest on the earlier of October 24, 2025, or the date of Bio-Techne's 2025 annual meeting of shareholders.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The director acquired shares and options, but also disposed of a larger number of shares. The overall impact is unclear without further context.
Positives
- The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.
Negatives
- The disposal of 44,559 shares of common stock could be interpreted negatively, although the acquisition of new shares and options may offset this concern.
Risks
- The Form 4 filing itself doesn't inherently present risks, but the market's interpretation of the transactions could impact the stock price.
- The vesting schedule of the new options is tied to the annual shareholder meeting, which could introduce uncertainty.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings for signals about management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders may react to the reported transactions, potentially influencing the stock price.
Key Dates
| Date | Description |
|---|---|
| 10/29/2016 | Stock Options (Right to Buy) exercisable date with an exercise price of $21.84 and expiration date of 10/28/2025. |
| 10/26/2017 | Stock Options (Right to Buy) exercisable date with an exercise price of $25.3 and expiration date of 10/27/2026. |
| 10/25/2018 | Stock Options (Right to Buy) exercisable date with an exercise price of $31.26 and expiration date of 10/26/2027. |
| 10/24/2019 | Stock Options (Right to Buy) exercisable date with an exercise price of $44.96 and expiration date of 10/25/2028. |
| 10/24/2020 | Stock Options (Right to Buy) exercisable date with an exercise price of $50.41 and expiration date of 10/24/2029. |
| 10/28/2021 | Stock Options (Right to Buy) exercisable date with an exercise price of $63.92 and expiration date of 10/29/2030. |
| 10/27/2022 | Stock Options (Right to Buy) exercisable date with an exercise price of $128.81 and expiration date of 10/28/2031. |
| 10/26/2023 | Stock Options (Right to Buy) exercisable date with an exercise price of $73.94 and expiration date of 10/27/2032. |
| 10/24/2024 | Date of transaction for common stock and stock options. |
| 10/24/2024 | Stock Options (Right to Buy) exercisable date with an exercise price of $61.51 and expiration date of 10/26/2033. |
| 10/24/2024 | Stock Options (Right to Buy) exercisable date with an exercise price of $68.37 and expiration date of 10/24/2034. |
| 10/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.